Literature DB >> 17961571

Cervical priming with misoprostol prior to transcervical procedures.

C Fiala1, K Gemzell-Danielsson, O S Tang, H von Hertzen.   

Abstract

Cervical priming with misoprostol has shown to facilitate transcervical procedures and to reduce side-effects. Cervical priming is recommended by several evidence-based guidelines prior to surgical abortion, dilatation and curettage, hysteroscopy and intrauterine device insertion. It is effective in pregnant as well as in non-pregnant women while the results in post-menopausal women are conflicting. Misoprostol is the best suited prostaglandin for a number of reasons: it has a short half-life, few side effects, it is stable at room temperature, it is relatively cheap and the dosage can easily be adjusted according to the clinical need. Various doses, routes, and time intervals between misoprostol application and the intervention have been evaluated. A single dose of 400 microg given sublingually or vaginally 3h before the intervention has given the best efficacy with the least side effects. Higher doses or longer intervals do not improve the effect on the cervix. Pain is a frequent side effect, but usually responds well to NSAIDs. Other side effects are rare.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17961571     DOI: 10.1016/j.ijgo.2007.09.005

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  10 in total

1.  A Comparative Study to Evaluate the Efficacy of Vaginal vs Oral Prostaglandin E1 Analogue (Misoprostol) in Management of First Trimester Missed Abortion.

Authors:  Sheeba Marwah; Supriya Gupta; Neera Parothi Batra; Vidhu Bhasin; Veena Sarna; Nirlep Kaur
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Uses of misoprostol in obstetrics and gynecology.

Authors:  Rebecca Allen; Barbara M O'Brien
Journal:  Rev Obstet Gynecol       Date:  2009

Review 3.  Practical advice for avoidance of pain associated with insertion of intrauterine contraceptives.

Authors:  Luis Bahamondes; Diana Mansour; Christian Fiala; Andrew M Kaunitz; Kristina Gemzell-Danielsson
Journal:  J Fam Plann Reprod Health Care       Date:  2013-09-27

4.  Analysis of cervical resistance during continuous controllable balloon dilatation: controlled clinical and experimental study.

Authors:  Petar Arsenijevic; Marko Milosevic; Aleksandar Zivanovic; Biljana Milicic; Branislav Jeremic; Nenad Filipovic; Zoran Protrka; Petar Todorovic; Slobodan Arsenijevic
Journal:  Trials       Date:  2015-10-28       Impact factor: 2.279

5.  Evaluation of isosorbide-5-mononitrate as a cervical ripening agent prior to induced abortion in contrast to misoprostol- a randomized controlled trial.

Authors:  Aloke Kumar De; Bhattacharyya Sanjoy Kumar; Aparna Chakraborty; Amrita Samanta
Journal:  Obstet Gynecol Sci       Date:  2019-08-09

6.  Mechanical dilatation of the stenosed cervix under local anesthesia: A prospective case series.

Authors:  Kirsty V Biggs; San Soo Hoo; Mallikarjun Kodampur
Journal:  J Obstet Gynaecol Res       Date:  2022-02-07       Impact factor: 1.697

7.  A combination of misoprostol and estradiol for preoperative cervical ripening in postmenopausal women: a randomised controlled trial.

Authors:  K S Oppegaard; M Lieng; A Berg; O Istre; E Qvigstad; B-I Nesheim
Journal:  BJOG       Date:  2010-01       Impact factor: 6.531

8.  Continuous controllable balloon dilation: a novel approach for cervix dilation.

Authors:  Slobodan Arsenijevic; Gordana Vukcevic-Globarevic; Vladislav Volarevic; Ivan Macuzic; Petar Todorovic; Irena Tanaskovic; Milan Mijailovic; Sasa Raicevic; Branislav Jeremic
Journal:  Trials       Date:  2012-10-22       Impact factor: 2.279

Review 9.  Cervical ripening before first trimester surgical evacuation for non-viable pregnancy.

Authors:  Kylie Webber; Rosalie M Grivell
Journal:  Cochrane Database Syst Rev       Date:  2015-11-10

10.  Computer simulation of cervical tissue response to a hydraulic dilator device.

Authors:  Nenad Filipovic; Dalibor Nikolic; Igor Saveljic; Irena Tanaskovic; Nebojsa Zdravkovic; Aleksandar Zivanovic; Petar Arsenijevic; Branislav Jeremic; Slobodan Arsenijevic
Journal:  Theor Biol Med Model       Date:  2013-11-06       Impact factor: 2.432

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.